MARKET

CVAC

CVAC

Curevac B.V.
NASDAQ
2.770
-0.210
-7.05%
After Hours: 2.860 +0.09 +3.25% 19:43 03/31 EDT
OPEN
2.930
PREV CLOSE
2.980
HIGH
2.930
LOW
2.720
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
5.28
52 WEEK LOW
2.215
MARKET CAP
621.42M
P/E (TTM)
5.20
1D
5D
1M
3M
1Y
5Y
1D
Biotech Alert: Searches spiking for these stocks today
TipRanks · 7h ago
How Peter Marks' FDA departure is impacting pharma, biotech stocks
Seeking Alpha · 7h ago
Weekly Report: what happened at CVAC last week (0324-0328)?
Weekly Report · 13h ago
CureVac (CVAC) Gets a Hold from Leerink Partners
TipRanks · 17h ago
Trump’s medical tariffs could significantly hurt these European healthcare firms
Seeking Alpha · 2d ago
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Seeking Alpha · 3d ago
Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
TipRanks · 3d ago
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
Benzinga · 3d ago
More
About CVAC
More
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Recently
Symbol
Price
%Change

Webull offers CureVac BV stock information, including NASDAQ: CVAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVAC stock methods without spending real money on the virtual paper trading platform.